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Abstract
Background: Complementary and alternative medicine (CAM) is becoming a popular treatment for modulating
diverse immune disorders. Phellinus linteus (P. linteus) as one of the CAMs has been used to modulate cancers,
inflammation and allergic activities. However, little evidence has been shown about its underlying mechanism of
action by which it exerts a beneficial role in dermatological disease in vivo. In this study, we examined the
immunomodulatory effects of P. linteus on experimental atopic dermatitis (AD) and elucidated its action
mechanism.
Methods: The immunomodulatory effect of total extract of P. linteus on IgE production by human myeloma
U266B1 cells was measured by ELISA. To further identify the effective components, P. linteus was fractionated into
methanol soluble, water soluble and boiling water soluble extracts. Each extract was treated to U266B1 cells and
primary B cells to compare their inhibitory effects on IgE secretion. To test the in vivo efficacy, experimental atopic
dermatitis (AD) was established by alternative treatment of DNCB and house dust mite extract into BALB/c mice.
Water soluble extract of P. linteus (WA) or ceramide as a positive control were topically applied to ears of atopic
mouse every day for 2 weeks and progression of the disease was estimated by the following criteria: (a) ear
thickness, clinical score, (b) serum total IgE, IgG and mite specific IgE level by ELSIA, (c) histological examination of
ear tissue by H&E staining and (d) cytokine profile of total ear cells and CD4
+ T cells by real time PCR and ELSIA.
Results: Treatment of total extracts of P. linteus to U266B1 inhibited IgE secretion. Among the diverse extracts of P.
linteus, water soluble extract of P. linteus (WA) significantly reduced the IgE production in primary B cells and B cell
line U266B1. Moreover, treatment of WA reduced AD symptoms such as ear swelling, erythema, and dryness and
decreased recruitment of lymphocyte into the inflamed site. Interestingly WA treatment significantly reduced IgE
level without affecting IgG levels and also down-regulated the levels of pathogenic cytokines (IL-4, IL-13, IL-12 and
IFN-γ) and chemokines (CCL17 and CCL22) involved in AD development.
Conclusions: Our study indicates that protective effect of water soluble extract of P. linteus in atopic dermatitis is
mediated by inhibiting IgE production and expression of AD associated pathogenic cytokines as well as
chemokines, suggesting the beneficial effect of P. linteus to modulate allergic skin disease.
Background
Atopic dermatitis (AD) is a chronic inflammatory skin
disease characterized by pruritic and eczematous skin
lesions. The incidence of AD has rapidly increased espe-
cially in the industrialized countries and 10-20% of
children in the world suffer from this disease [1]. AD is
caused by complex pathogenic factors including genetic
susceptibility, environment trigger, skin barrier dysfunc-
tion, bacterial infection and immune dysregulation [2].
AD is a complex immune reaction mediated by both T
helper 1 (Th1) and Th2 immune responses. Th2 type
cytokines including IL-4, IL-5 and IL-13 play important
role in the development of AD by increasing the levels
of serum IgE and blood eosinophils in AD patients [3].
Th1 type IFN-γ is also involved in the maintenance of
* Correspondence: imsh@gist.ac.kr
1School of Life Sciences and Immune Synapse Research Center, Gwangju
Institute of Science and Technology (GIST), 261 Cheomdan-gwagiro, Buk-gu,
Gwangju 500-712, Korea
Full list of author information is available at the end of the article
© 2012 Hwang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Hwang et al. BMC Complementary and Alternative Medicine 2012, 12:159
http://www.biomedcentral.com/1472-6882/12/159chronic stage of AD by elevating the expression of
CCL17 (TARC) and CCL22 (MDC) that are involved in
the recruitment of effector T cells to the inflamed site
[4]. IFN-γ increases the sensitivity of Fas-mediated apop-
tosis of keratinocytes, which is considered to be a key
pathogenic event in eczematous dermatitis [5]. This im-
munological complexity associated with Th1/Th2 im-
mune dysregulation makes it hard to properly modulate
the AD symptoms. Although topical steroid therapy is
widely used for the treatment of AD patients, diverse
side effects limits its application. Development of new
treatment methods is being initiated with herbal medi-
cine with similar effectiveness but less side effects [6].
Phellinus linteus (P. linteus) has been known for its
anti-cancer activity [7,8]. Recently, several reports sug-
gested the anti-inflammatory and anti-allergic properties
of this mushroom. N-butanol fraction of P. linteus inhib-
ited croton-oil induced mouse edema in a dose
dependent manner [9]. P. linteus extract reduces IgE
production by increasing increased IFN-γ production
[10]. Furthermore, boiling water fraction from mycelium
of P. linteus inhibited mouse triphasic cutaneous reac-
tion [11]. However, still the exact therapeutic effects of
P. linteus and its underlying mechanisms in atopic
dermatitis are unclear.
In the present study, we examined the therapeutic
effects of cultured mycelium of P. linteus on the devel-
opment of experimental AD in mice. Water soluble ex-
tract of P. linteus (WA) suppressed the IgE production
by primary B cells and B cell line U266B1. Topical appli-
cation of water soluble extract of P. linteus (WA) inhib-
ited AD development by down-regulation of AD
associated pathogenic cytokines and chemokines and by
inhibition of lymphocytes infiltration into the inflamed
skin region.
Methods
Animals
Female BALB/cCrSlc mice (6–8 weeks) were purchased
from SLC Inc. (Hamamatsu, Japan). Mice were housed
in specific pathogen-free barrier facilities and used in ac-
cordance with protocols approved by the Animal Care
and Ethics Committees of the Gwangju Institute of Sci-
ence and Technology (GIST).
Fractionation and treatment of Phellinus linteus
Mycelium of P. linteus was kindly provided by Derma
Medico Co. (Seoul, Korea). Briefly, mycelium culture
was carried out in a medium containing 42.5% sucrose,
0.5% yeast extract and 0.1% MgCl2 in distilled water, pH
7.0 in a 300 mL flask and incubated at 25°C for 6 days
then separated by filter paper (Whatman
W) and freeze
dried. Ground dried mycelium of P. linteus dissolved in
PBS was used to examine the effect of total P. linteus
extracts (Figure 1). Constituents of the dried mycelium
were extracted sequentially with chloroform, methanol,
water and boiling water (Figure 2A). The extract was fil-
tered and the supernatant was concentrated with a ro-
tary evaporator and then freeze-dried resulting in a
powder extract. Endotoxin level of each fraction measured
by using Limulus Amebocyte Lysate kit (CAMBREX, East
Rutherford, NJ, USA) was less than 50 EU/mg. The water
soluble extract was dissolved in PBS (50 mg/ml) and 20 μl
of water soluble extract was painted to the surface of both
ear lobes every day during the induction period. The pro-
cedure and the yield of each fraction are summarized in
Figure 2A.
WST-1 assay
Cytotoxicity of P. linteus extract was conducted using
EZ-Cytox cell viability assay kit (Daeil Lab Service Co,
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Figure 1 Treatment of P. linteus inhibits IgE production in B cell line. (A) Various concentrations of P. linteus extract were treated to U266B1
cell lines for 72 hrs and cell viability was measured by MTT assay. (B) U266B1 cells were stimulated with P. linteus (0.5 mg/ml) in the presence or
absence of LPS (10 μg/ml), IL-4 (5 ng/ml) for 72 hrs and IgE levels in the culture supernatants were determined by ELISA. Error bars indicated S.D.
One (*), two (**) and three asterisk (***) indicates P<0.05, P<0.005, P<0.001, respectively. Data are representative of three independent
experiments.
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Briefly, 5 × 10
3 cells/well were dispensed in a 96 well
plates and incubated for 24 hrs. Various concentrations
of P. linteus extract were treated to the cells for 72 hrs
and then incubated with 10 μl of reagent for 1 hr. Using
the microplate reader, the absorbance was measured at
420–480 nm. Data was presented by relative growth in-
hibition compared to PBS-treated cells.
Measurement of IgE secretion from U266B1 cells
Human U266B1 multiple myeloma cells (ATCC TIB-
196
TM, American Type Culture Collection, USA) were
cultured at 37°C under 5% CO2 incubator. RPMI 1640
medium supplemented with 10% FCS, 1 mM sodium
pyuvate, 2 mM L-glutamine, 100 U penicillin and 50 μg/ml
streptomycin was used as a culture medium. Cells (1 × 10
6
cells/well) were stimulated with LPS (10 μg/ml), IL-4
(5 ng/ml) and P. linteus extract (0.5 mg/ml) for 72 hrs. The
supernatants were harvested for IgE assay by Sandwich
ELISA (BETHYL, Montgomery, TX, USA).
Isolation of B220
+ B cells and measurement of IgE
production
Draining lymph nodes (superficial cervical, axillary, bran-
chial lymph node) and spleen from normal BALB/c mice
are grinded using cell strainer (BD Biosciences, San
Diego, CA, USA), then B cells were isolated with B220
+ B
cell isolation bead (Miltenyi Biotech, Germany) and
columns (Miltenyi Biotech, Germany) by following the
manufacture’s protocol. To measure the secreted IgE level,
primary B cells were stimulated with LPS (10 μg/ml), IL-4
(5 ng/ml) and various concentration of WA for 72 hrs
then IgE concentration in the soup was measured by
ELISA (BD Biosciences, San Diego, CA, USA).
Induction of atopic dermatitis in the mouse ear
For the induction of atopic dermatitis, the surfaces of
both ear lobes of mice were stripped with surgical tape
(Nichiban, Japan). After stripping, 20 μlo f1 %2 ,4 -
dinitrochlorobenzene (DNCB)(Sigma Aldrich, St Louis,
MO, USA) dissolved in acetone/olive oil solution (acetone :
olive oil=1:3) was painted on each ear. After 3 days, 20 μl
A Total mycelium of P. linteus
Chloroform-soluble [0.28% ] Residue
Methanol soluble [47%] Residue
Water soluble [6.8%] Residue
Boiling water soluble [2%] Residue
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Figure 2 Water soluble extract of P. linteus (WA) treatment reduces IgE secretion by B cells. (A) Dried mycelium of P. linteus was extracted
sequentially with chloroform, methanol, water and boiling water and then the fractions were freeze-dried resulting in a powdered extract. The
yield of each fraction was indicated in the bracket. (B) The effect of each extract of P. linteus, ME (methanol soluble fraction), WA (water soluble
fraction), BW (boiling water soluble fraction) on the secretion of IgE from U266B1 cell line was measured by ELISA. (C) B220+ B cells were isolated
from lymph nodes and spleen of BALB/c mice. These primary B cells were stimulated with LPS (10 μg/ml), IL-4 (5 ng/ml) and various
concentrations of WA for 72 hrs and IgE level was measured by ELISA. Error bars indicated S.D. One (*), two (**) and three asterisk (***) indicates
P<0.05, P<0.005, P<0.001, respectively. Data are representative of three independent experiments.
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GREER source materials, Lenoir, NC, USA) dissolved in
PBS containing 0.5% tween 20 was re-painted. Chal-
lenge of DNCB and mite extract was repeated once a
week alternatively until 4 weeks. After 2 weeks of AD
induction, mice were divided into 3 groups that have
similar serum IgE levels. Then AD mice were treated
daily with PBS (Cont), 1 mg/each ear of water soluble
extract of P. linteus (WA) or 15 μg/each ear of ceramide
(Cera) (C2-ceramice, Cayman chemical, Ann Arbor,
Michigan, USA) until end of 4 weeks induction. Only
tape stripping and PBS-painted group was used as a
control (W/O).
Measurement of ear swelling and clinical score
Ear thickness was measured 24 hrs after application of
DNCB or mite extract with a dial thickness gauge (Kori
Seiki MFG, Co., LTD., Japan). Mouse with representative
clinical score of each group was photographed to show
the clinical symptoms. Clinical symptoms of each mouse
were evaluated as previously described [12]. Briefly, ery-
thema, edema, excoriation and dryness on the ear sur-
face was scored as 0 (not visible), 1 (mild), 2 (moderate),
3 (severe). Scoring was performed by three independent
observers, and the final score was taken as an average
for each group.
Histological evaluation
Excised ears of each group were fixed in 4% paraformalde-
hyde for 16 hrs and embedded in paraffin. Then, 6 μm
sections were stained with hematoxylin (Sigma Aldrich,
St Louis, MO, USA) and eosin (H&E) (Sigma Aldrich,
St Louis, MO, USA). Infiltrated lymphocytes, thickening
of the epidermis and fibrosis in the dermis were observed
by microscope.
mRNA isolation, cDNA synthesis, quantitative RT-PCR
The changes in the levels of cytokine and chemokine
mRNA expression in ears were determined by quantita-
tive RT-PCR (qRT-PCR). Total RNA was isolated from
ears of each group with TRIZol reagent (Molecular Re-
search center, Cincinnati, OH, USA) according to manu-
facturer’s protocol. Reverse transcription was performed
with reverse transcriptase primed by oligo (dT) primer
(Promega, Madison, WI, USA). The synthesized cDNA
were amplified by real-time PCR with specific primers:
murine L32 (Forward 50-GCC CAA GAT CGT CAA
AAA GA-30 and Reverse 50-ATT GTG GAC CAG GAA
CTT GC-30), IL-4 (Forward 50-ACA GGA GAA GGG
ACG CCA T-30 and Reverse 50-GAA GCC GTA CAG
ACG AGC TCA-30), IL-5 (Forward 50-AGC ACA GTG
GTG AAA GAG AC-30 and Reverse 50-TCC AAT GCA
TAG CTG GTG ATT T-30), IL-10 (Forward 50-ATA
ACT GCA CCC ACT TCC CA-30 and Reverse 50-TCA
TTT CCG ATA AGG CTT GG-30), IL-12 (50-GGA
AGA CGG CAG CAG AAT A-30 and Reverse 50-AAC
TTG AGG GAG AAG TAG GAA TGG-30), IL-13 (For-
ward 50-GCA ACA TCA CAC AGG ACC AGA-30 and
Reverse 50-GTC AGG GAA TCC AGG GCT AC-30),
IFN-γ (Forward 50-TCA AGT GGC ATA GAT GTG
GAA GAA-30 and Reverse 50-TGG CTC TGC AGG
ATT TTC ATG-30), TNF-α (Forward 50-CAT CTT CTC
AAA ATT CGA GTG ACA A-30), CCL17 (Forward 50-
CAT GAG GTC ACT TCA GAT GCT G-30 and Reverse
50-CCT GGA ACA CTC CAC TGA GG-30), CCL22
(Forward 50-AGG TCC CTA TGG TGC CAA TGT-30
and Reverse 50-CGG CAG GAT TTT GAG GTC CA-
30), Eotaxin (Forward 50-TGA GAG GCT GAG ATC
CAA-3 and Reverse 50-CTG GGA GGT GAA GGA
AGT-30), CCL20 (Forward 50- T G CT C TT C CTT G
CTT TGG CAT GGG TA-30 and Reverse 50-TCT GTG
CAG TGA TGT GCA GGT GAA GC-30), CCR4 (For-
ward 50-TCT ACA GCG GCA TCT TCT TCA T-30 and
Reverse 50-CAG TAC GTG TGG TTG TGC TCT G-30).
The data was normalized using the expression levels of
L32. Relative expression level of the each gene in the ex-
perimental group was compared with that of the control
group.
Measurement of immunoglobulin levels
Bloods were obtained from each treatment group at
2 weeks and 4 weeks of AD induction. Total IgE levels
in the serum were measured using sandwich enzyme-
linked immunosorbent assay (ELISA) kit (BD Bios-
ciences, San Diego, CA, USA) by following the manufac-
turer’s protocol. For detection of mite specific IgE, mite
extract (100 μlo f1 0μg/ml/well) was coated in 96 well
plates remaining procedures were followed according to
the manufacture’s protocol. Antigen specific IgE levels
were indicated by O.D value. Mean absorbance of anti-
gen coated well minus mean absorbance of non-coated
well was used as the O.D value of the mite specific IgE
levels. For the detection of total IgG level, serum was
analyzed with mouse IgG ELISA kit (BETHYL, Mont-
gomery, TX, USA) by following the manufacturer’s
protocol.
Isolation of ear total cells and CD4
+ T cells
Ears were removed from each treatment group, cut into
three pieces and washed with RPMI medium and gently
stirred in Erlenmeyer flasks containing 25 ml of 1.0 mM
EDTA in 5% FBS for 20 mins at room temperature.
Then ear segments were minced, transferred into 50 ml
centrifuge tube containing 15 ml for RPMI without
serum and vigorously shaken for 15 seconds three times.
And the tissues were transferred into T flasks containing
10 ml of 0.5 mg/ml of Collagenase type V (Sigma
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shaking incubator. After incubation, the soup containing
ear total cells were centrifuged and washed with ice-cold
PBS. Among total cells, some cells were analyzed for
cytokines profile and then CD4
+ Tcells were isolated with
CD4
+ T cell isolation bead (Miltenyi Biotech, Germany)
and columns (Miltenyi Biotech, Germany) according to
the manufacture’sp r o t o c o l .
Cell culture and stimulation
The isolated primary cells were cultured in T cell media
containing DMEM (Invitrogen, Carlsbad, CA, USA) sup-
plemented with 10% FBS (Hyclone, USA), 3 mM L-
glutamine (Sigma Aldrich, St Louis, MO, USA), 10 mM
HEPES (Sigma Aldrich, St Louis, MO, USA), 100 U/ml
penicillin (Sigma Aldrich, St Louis, MO, USA) and 100
U/ml streptomycin (Sigma Aldrich, St Louis, MO, USA)
and 0.05 mM 2-beta-mercaptoethanol (Sigma Aldrich,
St Louis, MO, USA). For cytokine profile analysis, cells
were stimulated with PMA (0.5 μg/ml) and ionomycin
(1 μM) for 4 hrs.
Statistical analysis
A relative level of test group was compared with control
value set at 1 or 100%. For statistical analysis, a two-tailed
Student’s t-test was used to calculate the statistical signifi-
cance of the experimental data. The level of significance
was set at *P<0.05, **P<0.005 and ***P<0.001. Signifi-
cance was only indicated when appropriate.
Results
P. linteus extract reduces IgE production in B cell line
To find out the optimal concentration of P. linteus (PL)
extract for in vitro efficacy test, cytotoxicity of P. linteus
extracts was tested. Human U266B1 multiple myeloma
cells were cultured in the presence of various concentra-
tions of P. linteus extract for 72 hrs then relative viable
cells were measured by WST-1 assay (Figure 1A). Treat-
ment of low concentration of P. linteus (< 0.5 mg/ml)
was not toxic to cells rather enhanced viable cell num-
bers were observed due to the cell proliferation during
the culture periods. However, at 0.75 mg/ml viable cells
were suddenly decreased (Figure 1A). So based on this
result, 0.5 mg/ml of PL extract was applied to all the
in vitro experiments. Next we tested the effect of total
extracts of P. linteus on IgE production by U266B1 cells
that established from the peripheral blood of myeloma
patients and secrete highly levels of IgE [13]. Cells were
stimulated with LPS (10 μg/ml) and IL-4 (5 ng/ml) in
the presence of P. linteus extract or PBS as a control for
72 hrs and then the levels of IgE production in the cul-
ture supernatant were measured by ELISA. Treatment of
P. linteus extract significantly reduced IgE production
compared to control treatment in both without (W/O)
and LPS/IL-4 stimulation condition and inhibitory effect
by P. linteus was enhanced upon stimulation (Figure 1B).
Water soluble extract of P. linteus (WA) inhibits IgE
production
To further identify the potent inhibitory fraction on IgE
production, the mycelia of P. linteus were extracted with
methanol (ME), water (WA) and boiling water (BW) by
the sequential fractionation method as described in
Figure 2A. Each extract was adjusted to have the same
concentration (0.5 mg/ml) and added to the culture
media of U266B1 cells. Cells were stimulated with LPS
(10 μg/ml) and IL-4 (5 ng/ml) in the presence of indi-
cated extract of P. linteus or PBS (Cont) for 72 hrs and
then IgE level in the culture supernatants were mea-
sured by ELISA. Among the three extracts, WA signifi-
cantly suppressed IgE secretion compared to the control
(Figure 2B) while methanol (ME) or boiling water ex-
tract (BW) failed to do. To further check whether WA
can also effectively reduce IgE production by primary B
cells, WA was applied to mouse primary B cells. Indeed,
WA treatment significantly decreased IgE production in
a dose dependent manner (Figure 2C). These results in-
dicate that water soluble extract of P. linteus (WA) can
inhibit the IgE secretion by activated primary B cells.
Topical application of water soluble extract of P. linteus
(WA) alleviates the symptoms of experimental atopic
dermatitis
Then to evaluate the immunomodulatory function of
P. linteus in vivo, water soluble extract of P. linteus (WA)
was topically applied to the ears of atopic dermatitis (AD)
induced mice. Experimental AD was induced on the both
ears of BALB/c mice by alternative painting of DNCB and
mite extract for 2 weeks [14,15]. After 2 weeks of induc-
tion, mice were divided into 3 groups and daily painted
with PBS (Cont), water soluble extract of P. linteus (WA)
or ceramide (Cera) to both ears for 2 weeks. To compare
the therapeutic effects of WA, ceramide was employed as
a positive control [16-21]. Painting of WA significantly
reduced the AD symptoms including erythema, horny
substance, dryness, and scaling (Figure 3B) by reducing
ear thickness (Figure 3C) and clinical score (Figure 3D)
compared with the PBS-treated control group. Inter-
estingly, the therapeutic efficacy of WA was compar-
able to the ceramide-treated group. To further confirm
the visual evaluation of AD symptoms, histological
analysis on atopic ears was performed. Excised ears
from each group were stained with hematoxylin and
eosin and infiltrated lymphocytes, thickening of the
epidermis and fibrosis in the dermis were observed by
microscope. Indeed, compared with PBS-treated con-
trol group, WA treated group showed significantly
reduced number of infiltrated immune cells such as
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epidermis (Figure 3E). Collectively, these data sug-
gest that water soluble extract of P. linteus (WA)
has protective effect on the progression of murine atopic
dermatitis.
Water soluble extract of P. linteus (WA) reduces serum IgE
levels
Increased IgE level is the hall mark of atopic dermatitis
progression. To further test whether suppression of AD
progression by the treatment of WA is also associated
with changes in IgE levels, serum IgE levels were mea-
sured from each treatment group. After 14 and 30 days
of AD induction, serum was obtained from each treat-
ment group, and total IgE and mite specific IgE levels
were measured by ELISA. In control group, IgE levels
were increased in an induction time dependent manner.
However, topical application of WA significantly reduced
serum IgE levels which were comparable to that of cera-
mide treated mice (Figure 4A) without affecting serum
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WA significantly (p<0.005) reduced the mite specific
serum IgE levels even better than ceramide treated
group (Figure 4B). These data indicate that therapeutic
effect of water soluble extract of P. linteus (WA) in AD
progression is linked with down-regulation of serum IgE
levels.
Water soluble extract of P. linteus (WA) reduces the
expression of pathogenic cytokines and chemokines
Together with increased IgE levels, T helper (Th1),
Th2 type cytokines and chemokines also mediate pro-
gression of atopic dermatitis by recruiting lympho-
cytes, mast cells and eosinophils to the atopic skins.
We further examined whether suppression of AD pro-
gression by the treatment of WA is mediated by the
changes in the levels of AD associated cytokines and
chemokines in total ear cells or ear residual CD4
+ T
cells. Total ear cells isolated from each group were
stimulated with PMA (0.5 μg/ml) and ionomycin
(1 μM )f o r4h r sa n dt h ee x p r e s s i o n so fc y t o k i n e s
and chemokines were compared between the treat-
ment groups. In line with the histological analysis,
WA treatment significantly decreased CCL22 and
CCR4 expression levels (Figure 5A). Ceramide treat-
ment also significantly reduced CCL22 and CCR4 ex-
pression. In addition, treatment of WA significantly
decreased the expression of pathogenic cytokines [22]
including IL-2, IL-10, IL-12, IL-13 and IFN-γ and cer-
amide treatment significantly reduced IL-13 and TNF-
α expression (Figure 5B). Next, to further define the
effects of WA treatment on effector T cells, the ex-
pression levels of cytokines in ear residual CD4
+ T
cells were measured by quantitative RT-PCR. WA or
ceramide treatment significantly down-regulated
pathogenic cytokine expression such as IL-12, IL-13
and IFN-γ compared with PBS (Cont) (Figure 5C).
These data indicate that protective effect of WA in
AD progression is mediated by down-regulation of
pathogenic chemokines and cytokines in the inflamed
tissues, resulting in significant reduction of infiltrated
pathogenic immune cells.
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Figure 4 Water soluble extract of P. linteus (WA) reduces IgE levels in AD induced mice. After 2 and 4 weeks of AD induction, sera were
obtained from each group, and the levels of total IgE (A), antigen (mite)-specific IgE (B) and total IgG (C) were measured by ELISA. Error bars
indicated S.D. One (*), two (**) and three asterisk (***) indicates P<0.05, P<0.005, P<0.001, respectively. Data are representative of three
independent experiments.
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In this study, we identified a novel function of P. linteus
as a potent therapeutic modulator for atopic dermatitis
(AD) and elucidated the underlying action mechanisms
of it in alleviation of AD symptoms. Treatment of water
soluble extract of P. linteus (WA) significantly reduced
serum IgE and the levels of AD related pathogenic cyto-
kines and chemokines.
Atopic dermatitis is thought to be a typical Th2 type
immune disorder which shows elevated serum IgE level
and increment of Th2 type cytokines such as IL-4, IL-5
and IL-13 [23,24]. Th1 type response also plays key role
in pathogenesis and maintenance of AD [23]. Clinical
trials have been performed to modulate Th2 and Th1
type responses as well as chemokines levels. General im-
mune suppressants have been used to treat AD, which
cause numerous side effects with short period of efficacy.
Recently herbal medicines have become a major part of
CAMs (Complementary and Alternative Medicines) for
treatment various kinds of diseases including cancer, al-
lergy and diabetes [25]. These plant derived products
have been used as drugs and food additives for a long
time. However, scientific evidence is required for the fur-
ther development of herbal medicines and their clinical
application to treat diverse diseases. P. linteus is a mem-
ber of Hymenochaetaceae, which has been used as a
traditional medicine in oriental countries for the
treatment of various diseases such as gastroenteric dis-
order, inflammation, tumors and lymphopathic disease
[26,27]. Its pharmacological activities, especially anti-
tumor and anti-inflammatory activities, have been docu-
mented [28-30]. However no information is available on
the effect of mycelium of P. linteus in modulation of al-
lergic skin disorders such as atopic dermatitis.
In this study we aimed to test and identify effective
fraction of the mycelium of P. linteus in modulation of
atopic dermatitis. Since P. linteus has limited production
in nature, we used mycelium culture of P. linteus which
can be easily available in large quantities. To elucidate
whether P. linteus has therapeutic potential for atopic
dermatitis, we first tested inhibitory effect on IgE pro-
duction by B cells since serum IgE levels were consid-
ered as an authentic marker of AD. Indeed, 70~80% of
AD patients showed significantly increased serum IgE
level compared to non-AD patients. After determining
the non-cytotoxic concentration we applied total extract
of P. linteus into IgE producing U266B1 B cell lines and
found that the extract significantly inhibited IgE produc-
tion under the LPS and IL-4 stimulation which is the
well known IgE class switching condition [13,31] as well
as W/O stimulation (Figure 1B). To identify potent in-
hibitory fraction we further fractionated P. linteus by di-
verse solvents including chloroform, methanol, water
and boiling water (Figure 2A). Among the extracts,
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Figure 5 Water soluble extract of P. linteus (WA) inhibits the expression of pathogenic cytokines and chemokines in ear. After final
treatment, mice of each group were sacrificed and ears were removed. (A, B) Total ear cells were stimulated with PMA (0.5 μg/ml) and
ionomycin (1 μM) for 4 hrs, then mRNA expression of chemokines (A) and cytokines (B) were determined by quantitative RT-PCR. (C) CD4+ T cells
isolated from ear total cells were stimulated and cytokine levels were measured by quantitative RT-PCR. The mRNA expression levels in each
group were normalized with L32 (house- keeping gene) and then fold induction of each target gene were compared to Cont (PBS) group. Error
bars indicated S.D. One (*), Two (**) and three asterisk (***) indicates P<0.05, P<0.005, P<0.001, respectively. Data are representative of three
independent experiments.
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most potent inhibitory activity to block IgE production
in both U266B1 cell line and primary B cells (Figure 2B).
In accord with in vitro result, among the three fractions
only water soluble extract of P. linteus (WA) signifi-
cantly decreased total serum IgE levels from AD induced
mice (data not shown). Based on these results, we inves-
tigated the therapeutic effect of soluble extract of P. lin-
teus (WA) in ongoing AD model. We also used
ceramide [21] as a positive control to elucidate remedial
value of soluble extract of P. linteus (WA). It has been
reported that ceramide content is decreased in the skin
of AD patients [32] and ceramide content in the stratum
corneum showed a correlation with skin barrier function
in AD patients. Indeed, topical application of ceramide
derivatives suppressed AD-like skin lesions in NC/Nga
mice by inhibiting infiltration of leukocytes and mast
cells and reduced IL-4, TNF-α expression from ear cells
[33]. As expected, topical application of ceramide signifi-
cantly reduced AD symptoms, ear thickness and incre-
ment of clinical scores compared to PBS treatment
(Figure 3). Interestingly, treatment of water soluble ex-
tract of P. linteus (WA) showed comparable therapeutic
effects with ceramide in reducing AD symptoms such as
ear thickness and clinical score (Figure 3). Histological
analysis of ear tissues further indicated that treatment
water soluble extract of P. linteus (WA) significantly
decreased tissue infiltration of lymphocytes and granulo-
cytes compared with ear tissues from PBS treated con-
trol mice (Figure 3E). In addition, treatment of water
soluble extract of P. linteus (WA) significantly reduced
total IgE levels (Figure 4A) as well as in antigen (mite)-
specific IgE levels (Figure 4B) without affecting total IgG
levels (Figure 4C). Interestingly, water soluble extract of
P. linteus (WA) was more potent than ceramide in redu-
cing mite-specific IgE levels. These data indicated that
P. linteus can suppress allergic responses in an aller-
gen specific manner; consequently, this could be one
of the merits of P. linteus for the treatment of atopic
dermatitis.
AD pathogenesis is associated with recruitment of
lymphocyte, granulocyte to the inflammatory skin region.
During this multiple step process of leukocyte trafficking
and migration, chemokine ligand-receptor interactions are
considered as crucial factors. Several chemokines have as-
sociation with AD phenotype and among them, CCL17,
CCL22, CCR4 have pivotal roles in migration of patho-
genic immune cells (mainly CD4
+ Tcells) to the site of in-
flammation [34]. Interestingly, treatment of water soluble
extract of P. linteus (WA) significantly decreased the ex-
pression of CCL22 and CCR4 (Figure 5A). Since keratino-
cyte, epithelial cells and dendritic cells are major source of
these chemokines, suppression of chemokine expression
by the treatment of water soluble extract of P. linteus
(WA) could lead to lowering of infiltration of pathogenic
T cells at the site of inflammation (Figure 3E) [35-38].
Decreased expression of CCR4 also indicates that water
soluble extract of P. linteus (WA) could inhibit T cell dif-
ferentiation into Th2 cells since CCR4 is mainly expressed
on the surface of Th2 cells in AD patients. Inhibitory ef-
fect of water soluble extract of P. linteus (WA) on the che-
mokine expression was comparable with that of ceramide
(Figure 5A). Like chemokines, cytokines are also crucial
pathogenic factors in AD pathogenesis. BothTh1 and Th2
type cytokines contribute to the pathogenesis of AD and
their expression pattern is not mutually exclusive [39]. IL-
4, IL-5 and IL-13 are typical Th2 type cytokines which sti-
mulates Th2 differentiation and IgE production by B cells.
IL-12 and IFN-γ are typical Th1 type cytokines that in-
duce differentiation and maturation of T cells into Th1
type cells. Development of AD is induced by Th2 type re-
sponse, while the chronic inflammatory responses is dom-
inantly mediated by Th1 type reactions [40]. In addition,
house dust mite reactive T cells produce both Th1 and
Th2 type cytokines which strongly supports this concept
[41]. Therefore, for the treatment of AD, both Th1 and
Th2 types of immune responses should be considered as
therapeutic targets. To elucidate the underlying mechan-
ism of water soluble extract of P. linteus (WA), we mea-
sured mRNA expression levels of AD-related pathogenic
cytokines from ear tissues and ear residual CD4
+ Tc e l l s
(Figure 5B and 5C). In ear tissues, topical application of
water soluble extract of P. linteus (WA) significantly
reduced not only Th2 cytokines (IL-10 and IL-13) but also
Th1 cytokines (IL-12 and IFN-γ) (Figure 5B). IL-13 is
known as the major inducer of Th2 generation in the cu-
taneous microenvironment, independent of IL-4 [42]. IL-
12 may have critical roles to terminate Th2 cytokine ex-
pression but it also initiates expression of Th1 cytokine
IFN- γ which induces CCL17 (TARC) and CCL22 (MDC)
from keratinocyte and epithelial cells [43-45]. Interest-
ingly, treatment of water soluble extract of P. linteus
(WA) significantly decreased expression of MHCII, B7.1
and B7.2 in ear tissues of AD mice compared to PBS trea-
ted mice (data not shown). Hence, treatment with water
soluble extract of P. linteus (WA) may suppress activation
of antigen presenting cells including dendritic cells,
macrophage, keratinocyte and epithelial cells at the site of
inflammation, which modulates activation and differenti-
ation of CD4
+ T cells into Th1 or Th2 type. Interestingly,
treatment of water soluble extract of P. linteus (WA) more
significantly down-regulated the expression levels of IL-2,
IL-10, IL-12, and IFN-γ from ear cells compared to cera-
mide treatment (Figure 5B). Indeed, treatment with water
soluble extract of P. linteus (WA) significantly decreased
expression level of pathogenic cytokines including IL-12,
IL-13 and IFN- γ in CD4+ T cells of atopic regions and
the inhibitory effect was more efficient than ceramide
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ionomycin stimulation, under the antigen specific stimula-
tion by mite extract, WA also significantly decreased the
expression levels of pathogenic cytokines (IL-4, IL-13 and
IFN-γ) and chemokines (CCL22) and this effect was more
effective than ceramide treatment (Additional file 1: Figure
S1). Among the subfractions, water soluble extract of
P. linteus (WA) was the most effective in modulating AD-
associated inflammatory responses, implying that P. linteus
may contain active anti-inflammatory component(s) with
relatively hydrophilic characters. Further characterization
of active compound will lead to develop a potent AD
modulating agent. Topical treatment of ointment contain-
ing extract of P. linteus significantly decreased total serum
IgE levels. Furthermore, not only topical treatment of WA,
oral administration of WA also improved AD symptoms
including reduction of IgE levels, pathogenic cytokine ex-
pression and immune cell infiltrations (data not shown).
P. linteus is well known to exhibit anti-cancer effects
through immuno-potentiating effects and also anti-
inflammatory effects. Exact action mechanisms of anti-
tumor and anti-inflammatory effect might be mediated by
different active component. In addition, routes of treat-
ments such as oral administration or topical application
and target cells of P. linteus under the certain disease en-
vironment may mediate diverse effect of P. linteus on dif-
ferent immune disorders.
Collectively, topical application of water soluble ex-
tract of P. linteus (WA) may inhibit hyper-activation of
tissue residual antigen presenting cells, which subse-
quently block the initiation of immune cascade from in-
nate to adaptive immunity.
Conclusions
Although beneficial effects of P. linteus in various in-
flammatory diseases have been noticed for a long time,
the exact action mechanism was not clear. In this study
we have shown that topical application of water soluble
extract of mycelium of P. linteus (WA) inhibits the de-
velopment of experimental AD by reducing the infiltra-
tion of leukocytes and granulocytes and by decreasing
serum IgE levels. Thus our results indicate that water
soluble extract of mycelium of P. linteus (WA) could be
applicable as an effective complementary and alternative
medicine to modulate atopic symptoms.
Additional file
Additional file 1: Figure S1. Water soluble extract of P. linteus (WA)
inhibits the expression of pathogenic cytokines and chemokines under
the antigen specific stimulation. AD-induced mice were sacrificed and
ears were removed. Total ear cells were stimulated with WA (0.5 mg/ml)
or ceramide (10 μg /ml) in the presence of mite extract (5 μg /ml) for
24 hrs, then mRNA expression of chemokines (A) and cytokines (B) were
determined by quantitative RT-PCR. The mRNA expression levels of each
sample were normalized with L32 (house- keeping gene) and then fold
induction of each target gene were compared to PBS treated control.
Error bars indicated S.D. One (*), Two (**) and three asterisk (***) indicates
P<0.05, P<0.005, P<0.001, respectively. Data are representative of three
independent experiments.
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